The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.
 
Frederic Pouliot
Stock and Other Ownership Interests - Allogene Therapeutics
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Novartis; Tersera; Tolmar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Tersera; Tolmar
Speakers' Bureau - Astellas Pharma; Bayer; Janssen
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Merck (Inst); Tersera (Inst)
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Patrick O. Richard
Honoraria - Astellas Pharma; Bayer; Janssen; Knight Pharmaceuticals; Tolmar
Consulting or Advisory Role - Astellas Pharma; Bayer
Research Funding - Novartis
 
Stephan Probst
Honoraria - Advanced Accelerator Applications; Bayer; POINT Biopharma
Consulting or Advisory Role - Advanced Accelerator Applications; Lantheus Medical Imaging
Research Funding - Lantheus Medical Imaging; POINT Biopharma
 
Étienne Rousseau
Employment - Alpha-9 Theranostics (I)
Stock and Other Ownership Interests - Alpha-9 Theranostics (I)
 
Eric Levesque
No Relationships to Disclose
 
Vincent Castonguay
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS; Eisai; GlaxoSmithKline Canada; Ipsen; Janssen; Merck; Pfizer
Research Funding - AstraZeneca Canada (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Merck (Inst); Pfizer (Inst)
 
Nicolas Marcoux
Honoraria - AstraZeneca; Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer
 
Michele Lodde
No Relationships to Disclose
 
Jean-Baptiste Lattouf
Honoraria - Bristol-Myers Squibb; Knight Therapeutics; Tolmar
Consulting or Advisory Role - Bristol-Myers Squibb; Knight Therapeutics; Tolmar
Research Funding - AstraZeneca; Bristol-Myers Squibb
 
François-Alexandre Buteau
Honoraria - Lilly (I)
Consulting or Advisory Role - Bayer; Novartis
 
Daniel Juneau
Honoraria - AAA/Endocyte/Novartis
Consulting or Advisory Role - AAA/Endocyte/Novartis
 
Zineb Hamilou
No Relationships to Disclose
 
Michel Pavic
Honoraria - Bristol-Myers Squibb; Forus; Janssen; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Forus; Janssen; Lilly; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Merck; Novartis; Roche; Seagan
 
Jean-Francois Castilloux
No Relationships to Disclose
 
Atefeh Zamanian
No Relationships to Disclose
 
Guillaume Bouvet
No Relationships to Disclose
 
Amelie Tetu
No Relationships to Disclose
 
Brigitte Guérin
Patents, Royalties, Other Intellectual Property - TRASIS
 
Jean-Mathieu Beauregard
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis
Research Funding - Advanced Accelerator Applications/Novartis; Ipsen; POINT Biopharma